the chemokine is selected from the group consisting of ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1γ (murine macrophage inflammatory protein 1γ) and vMIPII (viral macrophage inflammatory protein II), and

a decrease in binding indicates that the test compound is an inhibitor of binding and an increase in binding indicates that the test compound is an enhancer of binding.

27. (Amended) The method of claim 25, wherein said contacting comprises contacting a cell expressing the polypeptide, fragment or variant.

Please add the following new claims:

37. (New) The method of claim 25, wherein the chemokine is labeled.

38. (New) The method of claim 37, wherein the label is selected from the group consisting of a fluorophore, a chemiluminescent agent, an isotope label, and an enzyme or a combination thereof.

39. (New) The method of claim 25, wherein the test compound is labeled.

40. (New) The method of claim 39, wherein the label is selected from the group consisting of a fluorophore, a chemiluminescent agent, an isotope label, and an enzyme or a combination thereof.

41. (New) The method of claim 25, wherein the CCX CKR polypeptide, fragment or variant is part of a cell fraction.

42. (New) The method of claim 25, further comprising formulating a modulator identified by the method as a pharmaceutical composition.

43. (New) The method of claim 25, wherein the chemokine is ELC.